USA flag logo/image

An Official Website of the United States Government

Enzyme replacement therapy of the brain in Mucopolysaccharidosis Type II

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43NS067707
Solicitation Year:
2011
Solicitation Topic Code:
NINDS
Solicitation Number:
PA10-050
Small Business Information
ARMAGEN TECHNOLOGIES, INC.
26679 Agoura Rd. #100 Calabasas, CA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Enzyme replacement therapy of the brain in Mucopolysaccharidosis Type II
Agency: HHS
Contract: 1R43NS067707-01A1
Award Amount: $111,214.00
 

Abstract:

DESCRIPTION (provided by applicant): Type II Mucopolysaccharidosis (MPS), also known as Hunter's syndrome, is an genetic disease that affects the lysosomal enzyme, iduronate-2-sulfatase (IDS). Consequently, patients with MPS-II develop extensive lysosomalstorage product accumulation in tissues, including the brain. Children develop multiple brain disorders including mental retardation and hydrocephalus. The current therapy for MPS-II is Enzyme Replacement Therapy (ERT) with the recombinant human protein.However, ERT does not treat the brain of MPS-II, because IDS does not cross the blood-brain barrier (BBB). The present work will re-engineer human IDS to enable transport across the BBB, using molecular Trojan horse technology. A molecular Trojan horse isa genetically engineered peptidomimetic monoclonal antibody (MAb) against an endogenous BBB peptide receptor, such as the human insulin receptor (HIR). The human IDS is fused to the heavy chain of the HIRMAb to create a new chemical entity, called the HIRMAb-IDS fusion protein. Preliminary studies show the HIRMAb-IDS fusion protein retains high IDS enzyme activity and high binding for the HIR. The present work will engineer a tandem vector for electroporation of host cells for development of a permantentlytransfected cell line to enable commercial production of the new fusion protein. The fusion protein will be purified with 2 columns and validated with HIR binding assays, IDS enzyme activity, Western blotting, and other biochemical assays. The biological activity of the HIRMAb-IDS fusion protein will be verified with assays in MPS-II fibroblasts that measure fusion protein uptake, cell IDS enzyme activity, and clearance of glycosoaminoglycans. These phase I studies will enable future phase II studies that test the safety, efficacy, and pharmacokinetics in animals prior to human testing. PUBLIC HEALTH RELEVANCE: Mucopolysacchridosis Type II, or Hunter's Syndrome, patients develop severe brain abrormalities, owing to the genetic defect in the gene encoding the lysosomal enzyme, iduronate-2-sulphatase (IDS). Enzyme replacement therapy (ERT) is not effective for the brain, because the IDS do not cross the blood-brain barrier (BBB). This research will develop a new treatment for the brain in patients withHunter's Syndrome, which involves the re-engineering of human IDS as a fusion protein that crosses the human BBB.

Principal Investigator:

Zhiqiang Lu
310-917-1275
jlu@armagen.com

Business Contact:

Paul Lee
310-917-1275
plee@armagen.com
Small Business Information at Submission:

ARMAGEN TECHNOLOGIES, INC.
914 COLORADO AVE SANTA MONICA, CA -

EIN/Tax ID: 177062671
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No